Luke Evnin Sells 43,198 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 43,198 shares of Werewolf Therapeutics stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $0.55, for a total transaction of $23,758.90. Following the completion of the sale, the director owned 2,266,671 shares in the company, valued at approximately $1,246,669.05. This trade represents a 1.87% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Luke Evnin also recently made the following trade(s):

• On Thursday, January 15th, Luke Evnin sold 37,413 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.55, for a total transaction of $20,577.15.
• On Wednesday, January 14th, Luke Evnin sold 30,616 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.57, for a total transaction of $17,451.12.
• On Monday, January 12th, Luke Evnin sold 58,980 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.57, for a total value of $33,618.60.
• On Friday, January 9th, Luke Evnin sold 24,678 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.61, for a total value of $15,053.58.
• On Thursday, January 8th, Luke Evnin sold 7,716 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total value of $4,861.08.
• On Wednesday, January 7th, Luke Evnin sold 11,915 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.64, for a total value of $7,625.60.
• On Tuesday, January 6th, Luke Evnin sold 40,761 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.65, for a total value of $26,494.65.
• On Monday, January 5th, Luke Evnin sold 18,378 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.64, for a total value of $11,761.92.
• On Friday, January 2nd, Luke Evnin sold 18,568 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total value of $11,697.84.
• On Wednesday, December 31st, Luke Evnin sold 24,962 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.62, for a total transaction of $15,476.44.

Werewolf Therapeutics Price Performance

Werewolf Therapeutics stock opened at $0.55 on Friday. The company has a fifty day simple moving average of $0.83 and a 200-day simple moving average of $1.23. The firm has a market capitalization of $26.66 million, a price-to-earnings ratio of -0.34 and a beta of 0.77. The company has a quick ratio of 3.87, a current ratio of 3.87 and a debt-to-equity ratio of 0.73. Werewolf Therapeutics, Inc. has a 52-week low of $0.53 and a 52-week high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.03. On average, equities analysts anticipate that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current fiscal year.

Institutional Trading of Werewolf Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Susquehanna International Group LLP raised its holdings in Werewolf Therapeutics by 16.9% in the 3rd quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock valued at $183,000 after buying an additional 13,439 shares during the period. Citadel Advisors LLC acquired a new stake in shares of Werewolf Therapeutics during the third quarter valued at about $304,000. Vanguard Group Inc. increased its position in shares of Werewolf Therapeutics by 8.5% during the third quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock valued at $2,774,000 after acquiring an additional 109,796 shares during the last quarter. Bridgeway Capital Management LLC raised its stake in shares of Werewolf Therapeutics by 157.7% in the 2nd quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock valued at $111,000 after acquiring an additional 62,414 shares during the period. Finally, Bank of America Corp DE lifted its holdings in shares of Werewolf Therapeutics by 1.2% in the 2nd quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock worth $2,321,000 after acquiring an additional 25,882 shares during the last quarter. 64.84% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

HOWL has been the subject of a number of analyst reports. Bank of America dropped their price target on Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a research report on Tuesday, November 18th. Zacks Research lowered Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 21st. Citigroup downgraded Werewolf Therapeutics from a “market outperform” rating to a “market perform” rating in a research note on Friday, December 19th. HC Wainwright reduced their price target on Werewolf Therapeutics from $10.00 to $4.00 and set a “buy” rating on the stock in a report on Friday, December 19th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Wednesday, October 8th. Three research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Werewolf Therapeutics has a consensus rating of “Hold” and an average target price of $3.75.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.